Protecting yourself from your assertions: navigating multiple regulatory schemes and disclosure.

Area of Science:

• Medical device regulation
• Intellectual property law

Background:

• The Food and Drug Administration (FDA) 510(k) process requires asserting substantial equivalence to predicate devices.
• The United States Patent and Trademark Office (USPTO) patent process demands asserting novelty and nonobviousness over prior art.

Purpose of the Study:

• To explore the risks associated with conflicting assertions made during FDA 510(k) and USPTO patent application processes for medical devices.
• To examine how 510(k) submissions can be used to invalidate a company's patent or demonstrate infringement of another's patent.

Main Methods:

• Analysis of the legal and regulatory implications of assertions made in both FDA 510(k) submissions and USPTO patent applications.
• Review of potential strategies for patent holders and accused infringers facing these conflicting requirements.

Main Results:

• Assertions of substantial equivalence in 510(k) submissions can potentially undermine patentability arguments for novelty and nonobviousness.
• Conversely, patent claims of novelty may conflict with 510(k) assertions of equivalence to existing devices.

Conclusions:

• Regulatory and patent counsel must collaborate to develop strategies that reconcile the requirements of substantial equivalence and novelty/nonobviousness.
• Minimizing risks requires careful navigation of both the FDA 510(k) and USPTO patent landscapes to avoid self-incrimination or invalidation.